Posted by Michael Wonder on 29 Feb 2024
Indapta Therapeutics receives US FDA fast track designation for lead clinical drug candidate IDP-023 for non-Hodgkin’s lymphoma and myeloma
29 February 2024 - Highly differentiated allogeneic natural killer cell therapy in Phase 1 trial, with initial data expected in second half of 2024.
Indapta Therapeutics today announced that the US FDA has granted fast track designation for its lead clinical program, IDP-023, for the treatment of patients with non-Hodgkin’s lymphoma and multiple myeloma.
